Star Combo Pharma Ltd. · ASX:S66

Star Combo Pharma — Investor Presentation (November 2021)

14 slides from Star Combo Pharma's investor presentation, Nov 4, 2021

  1. Slide 1: Star Combo Pharma Limited Investor presentation

    For personal use only STAR COMBO PHARMA LIMITED Investor presentation CEO Su Zhang November 2021

  2. Slide 2: Corporate snapshot

    Corporate snapshot For personal use only Star Combo Pharma Limited (ASX:S66) is a leading manufacturer and distributor of premium health and natural beauty products, with its development and manufacturing facilities located in Smithfield, New South Wales. Star Combo’s core strategy is to become Aust

  3. Slide 3: Key Themes FY21

    For personal use only Key Themes FY21 Resilience in contract manufacturing division despite COVID headwinds  Positive operating cash flow of $332K  Negative COVID impact on earnings with $6.3M non-cash asset writedown of Austoyou and Koala Mall  Construction and upgrade of multimillion dollar man

  4. Slide 4: Our Strategy

    For personal use only Our Strategy… 01 02 03 04 Organic growth through Capital investment in Maximising opportunity Expanding in new markets growing contract facilities upgrade to meet from macro trends manufacturing division domestic and overseas demand Offers shorter lead time in a Upgrade underwa

  5. Slide 5: Organic growth drivers

    For personal use only Organic growth drivers  Manufacturing a broad range of products with strong order book in place – Complementary medicines, nutraceuticals, vitamins/supplements, soft gel capsules, hard gel capsules, tablets, powders, liquid, sachet  Strong foot hold in domestic market with ex

  6. Slide 6: FY21 Results summary

    For personal use only FY21 Results summary A$M FY21 FY20 Operating revenue 26.72 38.84 Operating profit (loss) attributable to owners* (7.88) (0.35) Operating profit (loss) attributable to shareholders of s66* (7.89) (0.35) Operating cash flow 0.33 (1.02) Net tangible asset backing per ordinary shar

  7. Slide 7: Increase in production volume

    For personal use only Increase in production volume  Manufacturing division continues to perform strongly  A good start in Q1 FY22, production volume increased by 24% when compared with Q1 FY21 Units Manufactured Qty: million Q1 FY21 production volume increased by 24% to Q1 FY22 250 200 150 100 50

  8. Slide 8: Market dynamics

    For personal use only Market dynamics The Australian vitamin and dietary supplement category has doubled in  Australia’s complimentary medicine sector valued at size over 10 years $5.6BN*  Australia’s export of complementary medicine estimated to be $1.1BN*  7 out of 10 people have used at least

  9. Slide 9: Our people

    For personal use only Our people People Safety COVID Our team have demonstrated As a manufacturing business, A comprehensive COVID agility and tenacity in guiding we are dedicated to ensuring safety plan has been the business through the we have a safe workplace. implemented at Star Combo. uncertain

  10. Slide 10: Stage - Manufacturing facilities upgrade Woodpark Road

    For personal use only Stage 1 - Manufacturing facilities upgrade 171 Woodpark Road TGA – licensed nutraceutical manufacturing site Re-commenced expansion after works put on hold in July due to COVID restrictions Expansion involves • Upgrading existing facility • Installation of 13 new production lin

  11. Slide 11: Stage - Manufacturing facilities upgrade Woodpark Road (R&D centre)

    For personal use only Stage 2 - Manufacturing facilities upgrade 165 Woodpark Road Development Application approval received in August from Cumberland City Council to begin works and build R&D and Test Laboratory Centre Expansion involves • Building of new facility (see diagram) Rationale • Develop

  12. Slide 12: Achievements & Outlook

    For personal use only Achievements & Outlook Construction of Contract manufacturing FY21 Continued growth in Operating cash flow contract manufacturing positive with $17.3M in multimillion-dollar, business remains Achievements division cash in bank manufacturing facilities to increase capacity resil

  13. Slide 13: Investor relations

    For personal use only Investor relations investors@starcombo.com.au THANK YOU 13

  14. Slide 14: Disclaimer

    DISCLAIMER For personal use only The information in this presentation is not a prospectus or other form of disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act) and will not be lodged with the Australian Securities and Investments Comm

Star Combo Pharma — Investor Presentation (November 2021) on 6ix